Table 1.
Demographics of the Study Population
| HDV (n=62) |
HBV (n=240) |
HCV (n=701) |
HDV vs HBV |
HDV vs HCV |
|
|---|---|---|---|---|---|
| Mean Age (SD) | 39 (10) | 42 (13) | 47 (10) | 0.03 | <0.0001 |
| Male Gender (%) | 49 (79%) | 188 (78%) | 427 (61%) | 0.33 | 0.06 |
| Ethnicity | |||||
| White | 58% | 52% | 65% | 0.18 | 0.2 |
| Asian | 18% | 33% | 7% | ||
| Black/African American | 16% | 10% | 17% | ||
| Other | 3% | -- | 0.50% | ||
| Unknown | 5% | 6% | 10% | ||
| Laboratory Data (Mean and SD) | |||||
| ALT (U/L) | 134 (147) | 124 (95) | 95 (77) | 0.65 | 0.04 |
| AST (U/L) | 86 (72) | 76 (60) | 65 (49) | 0.28 | 0.03 |
| Platelets (K/uL) | 160 (70) | 182 (59) | 194 (67) | 0.02 | 0.0002 |
| Total Bilirubin (mg/dL) | 0.84 (0.62) | 0.85 (0.48) | 0.79 (0.44) | 0.88 | 0.55 |
| Albumin (g/dL) | 3.7 (0.6) | 3.8 (0.5) | 3.9 (0.4) | 0.17 | 0.003 |
| Alkaline Phosphatase (U/L) | 98 (45) | 83 (34) | 79 (36) | 0.02 | 0.003 |
| Modified HAI Inflammation Scores* | |||||
| Mean (SD) | 10.2 (3.3) | 7.7 (3.5) | 7.9 (2.8) | <0.0001 | <0.0001 |
| 0–4 | 2 (3.2%) | 39 (16.2%) | 67 (9.5%) | ||
| 5–8 | 19 (30.6%) | 105 (43.8%) | 334 (47.6%) | ||
| 9–12 | 18 (29.0%) | 70 (29.2%) | 262 (37.4%) | ||
| 13–18 | 21 (33.9%) | 26 (10.8%) | 38 (5.4%) | ||
| Ishak Fibrosis Stage | |||||
| Mean (SD) | 3.6 (1.5) | 2.4 (1.8) | 2.2 (1.8) | <0.0001 | <0.0001 |
| 0 | 1 (2%) | 126 (18%) | 29 (12%) | ||
| 1 | 6 (10%) | 159 (23%) | 74 (31%) | ||
| 2 | 2 (3%) | 136 (19%) | 24 (10%) | ||
| 3 | 27 (43%) | 107 (15%) | 57 (24%) | ||
| 4 | 8 (13%) | 97 (14%) | 18 (8%) | ||
| 5 | 8 (13%) | 26 (4%) | 17 (7%) | ||
| 6 | 10 (16%) | 51 (7%) | 23 (9%) | ||
*
2 HDV biopsies were not scored with HAI scoring system
HBV: Hepatitis B; HCV: Hepatitis C; HDV: Hepatitis D; ALT: alanine aminotransferase; AST: aspartate aminotransferase; SD: standard deviation; HAI: Histologic activity score